儿童CD19 CAR-T细胞治疗相关B细胞再生障碍的临床意义和对策

doi:10.12372/jcp.2024.24e0577

Abstract

Abstract:

B cell aplasia (BCA) is a common adverse side effect in pediatric patients with B-acute lymphoblastic leukemia (B-ALL) following CD19-chimeric antigen receptor T-cell (CD19 CAR-T) therapy. The duration of BCA has an impact on the immune status and prognosis of patients. A thorough understanding of BCA helps physicians choose treatment plans in a scientific, normative, and reasonable manner, reducing the risk of infection in pediatric leukemia patients after CAR-T treatment and improving their prognosis and quality of life.

Key words: B-acute lymphoblastic leukemia, CD19 CAR-T, B cell aplasia, child

LU Jun. The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients[J].Journal of Clinical Pediatrics, 2024, 42(7): 578-582.

References 30

[1]	Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539. doi: 10.3324/haematol.2020.247031 pmid: 33054110
[2]	Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 449-459.
[3]	Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial[J]. J Clin Oncol, 2023, 41(9): 1664-1669.
[4]	Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL[J]. Blood, 2019, 134(26): 2361-2368. doi: 10.1182/blood.2019001641 pmid: 31650176
[5]	Maria Gabelli, Macarena Oporto-Espuelas, Saskia Burridge, et al. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy[J]. Blood Adv, 2024, 8(8): 1959-1963.
[6]	Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia[J]. J Immunother Cancer, 2021, 9: e002287.
[7]	Deyà-Martínez A, Alonso-Saladrigues A, García AP, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia[J]. Bone Marrow Transplant, 2021, 56(2): 376-386.
[8]	Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131: 121-130. doi: 10.1182/blood-2017-07-793760 pmid: 29038338
[9]	Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20: 31-42. doi: S1470-2045(18)30864-7 pmid: 30518502
[10]	Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees[J]. J Allergy Clin Immunol, 2022, 149(5): 1525-1560. doi: 10.1016/j.jaci.2022.01.025 pmid: 35176351
[11]	Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448.
[12]	Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131: 121-130. doi: 10.1182/blood-2017-07-793760 pmid: 29038338
[13]	Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma[J]. Blood Adv, 2021, 5(1): 143-155. doi: 10.1182/bloodadvances.2020002732 pmid: 33570626
[14]	Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy[J]. Blood Adv, 2022, 6(7): 2045-2054.
[15]	Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380(1): 45-56.
[16]	Wu X, Cao Z, Chen Z, et al. Infectious complications in pediatric patients undergoing CD19⁺CD22⁺ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia[J]. Clin Exp Med, 2024, 24(1): 87.
[17]	Deyà-Martínez A, Alonso-Saladrigues A, García AP, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia[J]. Bone Marrow Transplant, 2021, 56(2): 376-386.
[18]	Arnold DE, Maude SL, Callahan CA, et al. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients[J]. Pediatr Blood Cancer, 2020, 67(3): e28092.
[19]	Hill JA, Giralt S, Torgerson TR, et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy[J]. Blood Rev, 2019, 38: 100596.
[20]	Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy[J]. Pediatr Blood Cancer, 2018, 65(4): 10.1002/pbc.26914.
[21]	Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper[J]. Infection, 2021, 49(2): 215-231.
[22]	Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells[J]. Biol Blood Marrow Transplant, 2020, 26(1): 26-33.
[23]	Bhella S, Majhail NS, Betcher J, et al. Choosing wisely BMT: American society for blood and marrow transplantation and Canadian blood and marrow transplant group's list of 5 tests and treatments to question in blood and marrow transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(5): 909-913.
[24]	Dourthe ME, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagen-lecleucel for B-cell acute lymphoblastic leukemia[J]. Leukemia, 2021, 35(12): 3383-3393.
[25]	Schultz LM, Eaton A, Baggott C, et al. Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia[J]. J Clin Oncol, 2023, 41(2): 354-363.
[26]	Jacoby E. The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia[J]. Bone Marrow Transplant, 2019, 54(Suppl 2): 810-814.
[27]	Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions[J]. J Allergy Clin Immunol Pract, 2022, 10(2): 460-466.
[28]	Gabelli M, Oporto Espuelas M, Bonney D, et al. ALL maintenance treatment for early loss of B-cell aplasia after tisagenlecleucel therapy[J]. Blood, 2021, 138(suppl 1): 3859.
[29]	Shiqi L, Jiasi Z, Lvzhe C, et al. Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T[J]. Mol Ther Oncolytics, 2023, 29: 107-117.
[30]	Holland EM, Molina JC, Dede K, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation[J]. J Immunother Cancer, 2022, 10(5): e004483.

The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 30

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LI Benshang, YANG Liu. Challenges and prospects of CAR-T treatment for pediatric disease [J]. Journal of Clinical Pediatrics, 2024, 42(7): 573-577.
[2]	SHANG Qianwen, ZHANG Yongzhan, LU Aidong, JIA Yueping, ZUO Yingxi, DING Mingming, ZHANG Leping, ZENG Huimin. The efficacy and safety of modified CLAG regimen for relapsed or refractory acute myeloid leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 589-594.
[3]	ZHAO Fenghua, ZHANG Yue, SUN Jin, YAN Shuangqin, LYU Lanqiu, MU Lijuan, YANG Jing, LUO Yan, YAN Dongmei, ZHAO Dongmei. Child-rearing problems of premature/low birth weight children aged 0 to 3 years: a multicenter cross-sectional study [J]. Journal of Clinical Pediatrics, 2024, 42(7): 606-612.
[4]	CHEN Zongzong, LI Xiaojing, HOU Chi, PENG Bingwei, WU Wenxiao, ZHU Haixia, WU Wenlin, TIAN Yang, CHEN Wenxiong. Clinical features and prognosis of immune-related brainstem encephalitis in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 626-630.
[5]	FENG Lian, HU Junlong, HUANG Hui, LI Xiaozhong, LI Yanhong. Predictive value of urinary CXCL10 for mortality risk of critically ill children in PICU [J]. Journal of Clinical Pediatrics, 2024, 42(7): 631-636.
[6]	CHEN Ye, ZHU Shanliang, YANG Shiwei, CHEN Jun, HUA Lichun, TANG Ying. The value of two-dimensional speckle tracking imaging in the assessment of left ventricular function in children with influenza A-related myocarditis [J]. Journal of Clinical Pediatrics, 2024, 42(7): 648-653.
[7]	WANG Huiying, TANG Jiazhong, SHANG Wenyuan, HUANG Jihong, LU Yanan, CHEN Sun. Analysis of factors influencing mechanical ventilation duration after surgery for congenital heart disease [J]. Journal of Clinical Pediatrics, 2024, 42(7): 654-658.
[8]	LI Niu, WANG Jian. Current status of database construction for rare diseases in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 663-666.
[9]	MA Tao, LU Jie, XU Hui, ZHAO Shunying, LI Huimin. Clinical characteristics of extrapulmonary tuberculosis in 473 children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 491-496.
[10]	GONG Ling, SHU Chang, RAN Haibo. Clinical characteristics and treatment outcomes of connective tissue disease-associated interstitial lung disease in children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 503-508.
[11]	LIANG Jiawei, MA Xiaohui, JIA Xuan. Study on the application value of the new Lake Louise criteria in children with myocarditis [J]. Journal of Clinical Pediatrics, 2024, 42(6): 526-532.
[12]	FAN Na, WANG Chunhui, ZHANG Anding, ZENG Lingchao, LI Yuanxia, LIN Yan, SHANG Lei, ZHANG Xinhui, HE Xiaobao, QI Ke, JIANG Xun. Correlation between functional constipation and the formation of appendiceal fecaliths in children with acute appendicitis [J]. Journal of Clinical Pediatrics, 2024, 42(6): 533-537.
[13]	MAO Meng, SHAO Jie, CHEN Jinjin, SHEN Lixiao. Interpretation of Catch-up growth in infants and young children with faltering growth: expert opinion to guide general clinicians [J]. Journal of Clinical Pediatrics, 2024, 42(5): 390-398.
[14]	XU Jiangshan, XU Xin, HE Shuang, LIU Qian, TIAN Jie, LYU Tiewei. Single center clinical analysis of radiofrequency ablation for children with cardiac enlargement and ventricular preexcitation [J]. Journal of Clinical Pediatrics, 2024, 42(5): 407-413.
[15]	LI Zhijuan, BAO Ying, HUANG Huimei, ZHANG Min, WANG Ying, NIU Yunhe, YANG Nan, SUO Lei, LIANG Nan. Clinical features and factors associated with diabetes mellitus in children-onset systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2024, 42(5): 419-424.